EA201591656A1 - Комбинированная терапия с ибрутинибом - Google Patents

Комбинированная терапия с ибрутинибом

Info

Publication number
EA201591656A1
EA201591656A1 EA201591656A EA201591656A EA201591656A1 EA 201591656 A1 EA201591656 A1 EA 201591656A1 EA 201591656 A EA201591656 A EA 201591656A EA 201591656 A EA201591656 A EA 201591656A EA 201591656 A1 EA201591656 A1 EA 201591656A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ibrutinib
combined therapy
bruton
btk
phenoxyphenyl
Prior art date
Application number
EA201591656A
Other languages
English (en)
Russian (ru)
Inventor
Бретт Холл
Кейт А. Сассер
Майкл Шаффер
Кук Дэвис
Тинеке Каснёф
Маттиас Версель
Виллем Листенберг
Бетти Чан
Срирам Баласубраманиан
Ричард Кроули
Хсу-Пин Куо
Original Assignee
Фармасайкликс Элэлси
Янссен Фармасеутика Энви
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармасайкликс Элэлси, Янссен Фармасеутика Энви filed Critical Фармасайкликс Элэлси
Publication of EA201591656A1 publication Critical patent/EA201591656A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EA201591656A 2013-04-08 2014-04-08 Комбинированная терапия с ибрутинибом EA201591656A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361809810P 2013-04-08 2013-04-08
PCT/US2014/033378 WO2014168975A1 (en) 2013-04-08 2014-04-08 Ibrutinib combination therapy

Publications (1)

Publication Number Publication Date
EA201591656A1 true EA201591656A1 (ru) 2016-05-31

Family

ID=51689963

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591656A EA201591656A1 (ru) 2013-04-08 2014-04-08 Комбинированная терапия с ибрутинибом

Country Status (14)

Country Link
US (2) US20160287592A1 (enExample)
EP (1) EP2983670A4 (enExample)
JP (3) JP6575952B2 (enExample)
KR (1) KR20150141971A (enExample)
CN (2) CN105263496A (enExample)
AU (3) AU2014251028A1 (enExample)
BR (1) BR112015025711A8 (enExample)
CA (1) CA2908375A1 (enExample)
EA (1) EA201591656A1 (enExample)
HK (1) HK1215374A1 (enExample)
IL (2) IL241710B (enExample)
MX (2) MX369503B (enExample)
PH (2) PH12015502337A1 (enExample)
WO (1) WO2014168975A1 (enExample)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009088990A1 (en) 2008-01-04 2009-07-16 Intellikine, Inc. Certain chemical entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US20110224235A1 (en) 2008-07-16 2011-09-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
KR101580714B1 (ko) 2010-06-03 2016-01-04 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도
NZ612909A (en) 2011-01-10 2015-09-25 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
EA201490265A1 (ru) 2011-07-13 2014-12-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
SI2734522T1 (sl) 2011-07-19 2019-03-29 Merck Sharp & Dohme B.V. 4-IMIDAZOPIRIDAZIN-1-IL-BENZAMIDI IN 4-IMIDAZOTRIAZIN-1-IL-BENZAMIDI kot BTK-INHIBITORJI
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
JP6105578B2 (ja) 2011-07-21 2017-03-29 トレロ ファーマシューティカルズ， インコーポレイテッド 複素環式プロテインキナーゼ阻害剤
KR20250151610A (ko) 2012-06-04 2025-10-21 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
BR112015001690A2 (pt) 2012-07-24 2017-11-07 Pharmacyclics Inc mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
CA2890105C (en) 2012-11-01 2023-03-21 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US10202356B2 (en) 2013-03-14 2019-02-12 Tolero Pharmaceuticals, Inc. JAK2 and ALK2 inhibitors and methods for their use
US9464092B2 (en) 2013-03-15 2016-10-11 G1 Therapeutics, Inc. Transient protection of normal cells during chemotherapy
CN107417691B (zh) 2013-03-15 2020-06-26 G1治疗公司 高效的抗赘生剂和抗增生剂
JP6800750B2 (ja) * 2013-08-02 2020-12-16 ファーマサイクリックス エルエルシー 固形腫瘍の処置方法
WO2015023703A1 (en) 2013-08-12 2015-02-19 Pharmacyclics, Inc. Methods for the treatment of her2 amplified cancer
CA2928721C (en) 2013-10-25 2020-12-22 Pharmacyclics Llc Use of ibrutinib for treating and preventing chronic graft versus host disease
CA2931431A1 (en) 2013-12-05 2015-06-11 Acerta Pharma B.V. Therapeutic combination of a pi3k inhibitor and a btk inhibitor
JP2017509336A (ja) 2014-03-20 2017-04-06 ファーマサイクリックス エルエルシー ホスホリパーゼｃガンマ２及び耐性に関連した変異
ES2806506T3 (es) 2014-03-25 2021-02-17 Ono Pharmaceutical Co Agente profiláctico y/o agente terapéutico para el linfoma difuso de células B grandes
WO2015181633A2 (en) 2014-04-11 2015-12-03 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015161288A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use as anti-neoplastic and anti-proliferative agents
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
WO2015193740A2 (en) * 2014-06-17 2015-12-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor
DK3179991T3 (da) 2014-08-11 2021-12-06 Acerta Pharma Bv Terapeutiske kombinationer af en btk-inhibitor og en bcl-2-inhibitor
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
TW201628622A (zh) * 2014-11-17 2016-08-16 製藥公司 Tlr抑制劑與布魯頓氏(bruton's)酪胺酸激酶抑制劑之組合
WO2016090255A1 (en) * 2014-12-05 2016-06-09 Sriram Balasubramanian Biological markers for predicting responsiveness to ibrutinib and r-chop combination therapy and methods of using the same
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
MA41827A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
WO2016167236A1 (ja) 2015-04-13 2016-10-20 第一三共株式会社 Ｍｄｍ２阻害剤とｂｔｋ阻害剤との併用治療法
EA201792304A1 (ru) 2015-04-20 2018-03-30 Эпизайм, Инк. Комбинированная терапия для лечения рака
LT3613745T (lt) 2015-07-02 2021-10-11 Acerta Pharma B.V. (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamido kietosios formos ir vaistinės formos
MA42546A (fr) * 2015-07-31 2018-06-06 Pharmacyclics Llc Combinaisons d'inhibiteur de la tyrosine kinase de bruton et leurs utilisations
AU2016304172A1 (en) * 2015-08-03 2018-03-15 Gilead Sciences, Inc. Combination therapies for treating cancers
CA3000746A1 (en) * 2015-10-02 2017-04-06 Gilead Sciences, Inc. Combinations of the btk inhibitor gs-4059 with inhibitors selected from a jak, ask1, brd and/or mmp9 inhibitor to treat cancer, allergic disorders, autoimmune diseases or inflammatory diseases
WO2017087947A2 (en) * 2015-11-19 2017-05-26 Pharmacyclics Llc Method of treatment of follicular lymphoma with a btk inhibitor
WO2017223422A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
NZ749275A (en) 2016-07-01 2023-06-30 G1 Therapeutics Inc Synthesis of n-(heteroaryl)-pyrrolo[2,3-d]pyrimidin-2-amines
CN109715166A (zh) 2016-07-14 2019-05-03 深圳明赛瑞霖药业有限公司 癌症的治疗
MX395539B (es) * 2016-07-29 2025-03-25 Oncternal Therapeutics Inc Usos de compuestos de indolinona
WO2018021890A1 (ko) * 2016-07-29 2018-02-01 이화여자대학교 산학협력단 크로메논 유도체 및 이를 포함하는 항암용 조성물
KR20240024296A (ko) 2016-12-05 2024-02-23 쥐원 쎄라퓨틱스, 인크. 화학요법 레지멘 동안의 면역 반응의 보존
JP7300394B2 (ja) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害
CN109937041B (zh) * 2017-05-18 2022-04-12 江苏恒瑞医药股份有限公司 一种ezh2抑制剂与btk抑制剂联合在制备治疗肿瘤的药物中的用途
EP3684367A1 (en) * 2017-09-19 2020-07-29 Cipla Limited Compositions comprising ibrutinib and an alkaloid having enhanced bioavailability
TW201922256A (zh) 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 治療淋巴樣惡性疾病之方法
EA202092154A1 (ru) * 2018-03-21 2021-03-22 Мей Фарма, Инк. Комбинированная терапия
BR112020020246A8 (pt) 2018-04-05 2022-10-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de cinase axl e uso dos mesmos
CN112236139A (zh) 2018-04-13 2021-01-15 大日本住友制药肿瘤公司 用于治疗骨髓增殖性肿瘤和与癌症相关的纤维化的pim激酶抑制剂
EP3787751A1 (en) 2018-05-03 2021-03-10 Juno Therapeutics, Inc. Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
EP3826684A4 (en) 2018-07-26 2022-04-06 Sumitomo Dainippon Pharma Oncology, Inc. METHODS OF TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL ACVR1 EXPRESSION AND ACVR1 INHIBITORS FOR USE IN THE SAME
AU2019314819A1 (en) * 2018-07-31 2020-10-22 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
SG11202101807SA (en) 2018-08-24 2021-03-30 G1 Therapeutics Inc Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one
US20210222228A1 (en) * 2018-08-26 2021-07-22 Cardiff Oncology, Inc. Plk1 target phosphorylation status and treatment of cancer with plk1 inhibitors
US20220362357A1 (en) * 2018-08-31 2022-11-17 Stichting Radboud Universitair Medisch Centrum Synergistic Combinations of Amino Acid Depletion Agent Sensitizers (AADAS) and Amino Acid Depletion Agents (AADA), and Therapeutic Methods of Use Thereof
CA3112421A1 (en) * 2018-09-12 2020-03-19 Denovo Biopharma Llc Combination of enzastaurin and inhibitors of btk and uses thereof
US20200171001A1 (en) * 2018-11-30 2020-06-04 Aptose Biosciences Inc. Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations
SG11202105309YA (en) * 2018-11-30 2021-06-29 Janssen Biotech Inc Methods of treating follicular lymphoma
JP7662528B2 (ja) 2019-02-12 2025-04-15 スミトモ ファーマ アメリカ， インコーポレイテッド 複素環式タンパク質キナーゼ阻害剤を含む製剤
KR20210129111A (ko) * 2019-02-15 2021-10-27 얀센 바이오테크 인코포레이티드 B-세포 악성종양의 치료를 위한 병용 요법
WO2020186149A1 (en) * 2019-03-13 2020-09-17 The Brigham And Women's Hospital, Inc. Targeting regulatory b cells and their regulators for cancer immunotherapy
CN115023240B (zh) * 2020-02-05 2024-08-23 卡尔那生物科学株式会社 抗癌剂组合物
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
GB202009764D0 (en) * 2020-06-26 2020-08-12 Cambridge Entpr Ltd Therapeutic treatment using protein kinase c (pkc) inhibitors and cytotoxic agents
US20230010803A1 (en) * 2021-06-30 2023-01-12 Janssen Pharmaceutica Nv Treatments for diffuse large b-cell lymphoma
WO2023285677A1 (en) * 2021-07-16 2023-01-19 Spexis Ag Pharmaceutical combinations for treating cancer
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
CN115554301A (zh) * 2022-10-24 2023-01-03 徐诺药业(南京)有限公司 Hdac抑制剂和伊布替尼在制备预防或者治疗套细胞淋巴瘤的药物中的用途
EP4611753A1 (en) 2022-10-31 2025-09-10 Sumitomo Pharma America, Inc. Pim1 inhibitor for treating myeloproliferative neoplasms

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008001156A1 (en) * 2006-06-26 2008-01-03 Centre Regional De Lutte Contre Le Cancer - Centre Francois Baclesse CANCER THERAPY USING BcI-XL-SPECIFIC siNA
DK2529622T3 (en) * 2006-09-22 2018-05-07 Pharmacyclics Llc INHIBITORS OF BRUTON-TYROSINKINASE
US20100041140A1 (en) * 2007-03-02 2010-02-18 Mdrna, Inc. Nucleic acid compounds for inhibiting bcl2 gene expression and uses thereof
JP5832721B2 (ja) * 2007-03-14 2015-12-16 バイオンシル・エス．アール．エル．Ｂｉｏｎｓｉｌ Ｓ．Ｒ．Ｌ． 上皮腫瘍細胞における薬剤耐性のモジュレータ化合物
EP2260026B1 (en) * 2008-03-27 2011-06-22 Janssen Pharmaceutica, N.V. Quinazolinone derivatives as tubulin polymerization inhibitors
PE20120345A1 (es) * 2009-05-26 2012-05-17 Abbvie Bahamas Ltd Derivados de 2-(1h-pirrolo[2,3-b]piridin-5-iloxi)-n-fenilsulfonilbenzamida como inhibidores de proteinas anti-apoptoticas
KR101580714B1 (ko) * 2010-06-03 2016-01-04 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도
CN111437386A (zh) * 2012-09-07 2020-07-24 吉宁特有限公司 II型抗CD20抗体与选择性Bcl-2抑制剂的组合治疗

Also Published As

Publication number Publication date
EP2983670A1 (en) 2016-02-17
PH12020552065A1 (en) 2021-05-10
BR112015025711A2 (pt) 2017-07-18
AU2019203205A1 (en) 2019-05-30
JP2020002146A (ja) 2020-01-09
HK1215374A1 (zh) 2016-08-26
JP6575952B2 (ja) 2019-09-18
AU2014251028A1 (en) 2015-11-05
JP2021119150A (ja) 2021-08-12
EP2983670A4 (en) 2017-03-08
CA2908375A1 (en) 2014-10-16
JP2016521266A (ja) 2016-07-21
IL263026A (en) 2018-12-31
AU2021200066A1 (en) 2021-03-18
BR112015025711A8 (pt) 2019-12-17
US20200368235A1 (en) 2020-11-26
MX369503B (es) 2019-11-11
IL241710B (en) 2018-11-29
WO2014168975A1 (en) 2014-10-16
PH12015502337A1 (en) 2016-02-22
US20160287592A1 (en) 2016-10-06
CN111317821A (zh) 2020-06-23
MX2019013429A (es) 2020-09-21
MX2015013970A (es) 2016-07-08
KR20150141971A (ko) 2015-12-21
CN105263496A (zh) 2016-01-20
JP6871978B2 (ja) 2021-05-19

Similar Documents

Publication Publication Date Title
EA201591656A1 (ru) Комбинированная терапия с ибрутинибом
EA201690746A1 (ru) Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии
PH12015502053A1 (en) Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors
ZA202502152B (en) Crystalline forms of a bruton's tyrosine kinase inhibitor
MX2021015370A (es) Composiciones farmaceuticas de un inhibidor de tirosina cinasa de bruton.
MX2017012411A (es) Co-cristales de un inhibidor de tirosina cinasa de bruton.
HK1228260A1 (en) Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
PH12016500743A1 (en) Treatment using bruton`s tyrosine kinase inhibitors and immunotherapy
TW202600141A (zh) 布魯東氏(bruton’s)酪胺酸激酶抑制劑之醫藥調配物
BR112018076622A2 (pt) pirrolo[2,3-d]piridazin-4-onas e pirazolo[3,4-d]piridazin-4-onas substituídas como inibidores de proteína cinase